SEC Form 4 · accession 0001179110-18-000069
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip S Low
Officer — Chief Science Officer · Director
Period of report
Dec 28, 2017
Accepted (ET)
Jan 2, 2018 · 3:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 28, 2017 | M | 65,445 | $3.06 | A | 354,050 | D | |
| Common StockF1 | Dec 28, 2017 | S | 50,511 | $4.4114 | D | 303,539 | D | |
| Common StockF2 | Dec 22, 2017 | G | 8,333 | $0.00 | D | 184,985 | I | By spouse trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.06 | Dec 28, 2017 | M | 65,445 | D | — | Feb 12, 2018 | Common Stock | 65,445 | 0 | D |
Explanation of responses
- F1Represents the sale of 50,511 shares in multiple transactions, ranging in price from $4.2700 to $4.5100 per share, resulting in a weighted average sale price per share of $4.4114. These shares were sold to cover the option exercise cost, taxes and fees in connection with the reporting person's exercise of stock options on December 28, 2017 as reported herein. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
- F2Represents a gift of 8,333 shares by Spouse Trust to a non-profit organization.
- F3The option is fully vested and immediately exercisable.